Patience Needed On US Biosimilars, Says Samsung Bioepis’ Ko
Expectations For US Biosimilars ‘May Have Been Excessive’
Executive Summary
In the first part of an exclusive interview with Generics Bulletin, Samsung Bioepis CEO Christopher Hansung Ko sets out his views on the US biosimilar market.